Russell Investments Group Ltd. held its stake in Verastem, Inc. (NASDAQ:VSTM) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 46,192 shares of the biopharmaceutical company’s stock at the end of the second quarter. Russell Investments Group Ltd. owned 0.12% of Verastem worth $101,000 as of its most recent SEC filing.

Separately, Renaissance Technologies LLC grew its stake in Verastem by 20.0% in the 1st quarter. Renaissance Technologies LLC now owns 1,226,600 shares of the biopharmaceutical company’s stock valued at $2,539,000 after purchasing an additional 204,400 shares during the period. 24.19% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Russell Investments Group Ltd. Has $101,000 Holdings in Verastem, Inc. (VSTM)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at

Shares of Verastem, Inc. (VSTM) traded up 0.43% on Friday, hitting $4.70. The stock had a trading volume of 592,915 shares. The stock has a 50 day moving average of $3.98 and a 200-day moving average of $2.71. Verastem, Inc. has a 12 month low of $1.05 and a 12 month high of $5.71. The stock’s market cap is $173.86 million.

Verastem (NASDAQ:VSTM) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.02). Equities research analysts anticipate that Verastem, Inc. will post ($1.38) EPS for the current year.

VSTM has been the subject of a number of recent analyst reports. Oppenheimer Holdings, Inc. set a $6.00 price objective on Verastem and gave the company a “buy” rating in a research note on Sunday, June 4th. Cann restated a “buy” rating on shares of Verastem in a research note on Wednesday, August 16th. HC Wainwright set a $7.00 price objective on Verastem and gave the company a “buy” rating in a research note on Thursday, August 10th. Zacks Investment Research upgraded Verastem from a “hold” rating to a “buy” rating and set a $3.75 price objective for the company in a research note on Thursday, July 13th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $1.50 price objective on shares of Verastem in a research note on Wednesday, June 28th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $5.04.

Verastem Company Profile

Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.

Want to see what other hedge funds are holding VSTM? Visit to get the latest 13F filings and insider trades for Verastem, Inc. (NASDAQ:VSTM).

Institutional Ownership by Quarter for Verastem (NASDAQ:VSTM)

Receive News & Stock Ratings for Verastem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc. and related stocks with our FREE daily email newsletter.